BBT-401 Shows Potential for Treatment of Ulcerative Colitis, Early Trials Reveal

BBT-401 Shows Potential for Treatment of Ulcerative Colitis, Early Trials Reveal
The investigational therapy BBT-401 effectively prevented ulcerative colitis symptoms in mice and rat models of the disease, and was shown to be safe and well-tolerated in healthy volunteers in a Phase 1 trial, its developer Bridge Biotherapeutics announced. With these results, the company is set to launch a Phase 2 trial (NCT03800420) to evaluate the potential of BBT-401 in patients with ulcerative colitis. Currently recruiting participants for the first cohort, the trial is expected to start in February 2019. The preclinical and Phase 1 clinical findings were discussed at the Crohn's & Colitis Congress held Feb. 7 to 9 in Las Vegas, NV. The session, “BBT-401 Is a Selective Pellino-1 Protein-Protein Interaction Inhibitor in Clinical Development Targeting a First-in-Class Drug for UC Treatment,” was presented by Gwanghee Lee, PhD, senior vice president of translational research at Bridge Biotherapeutics. BBT-401 is a potent and selective inhibitor of Pellino-1 protein, and was initially discovered by researchers at Sungkyunkwan University and Korea Research Institute of Chemical Technology. The compound was licensed to Bridge Biotherapeutics in 2015. By blocking Pellino-1 activity, BBT-401 prevents several important proteins, including MyD88 and NF-KB, from promoting the inflammatory process implicated in ulcerative colitis. The agent can also prevent the release of pro-inflammatory signaling molecules, including TNF-alpha and interleukin-6, among others. "Our team aims to develop the drug candidate as the first-in-class drug for ulcerative colitis as fast as possible to bring this novel compound to patients as a new treatment option, proving strong anti-inflammatory efficacy in active ulcerative colitis patients," Lee said in a press re
Subscribe or to access all post and page content.